drugset / Trial / NCT04163328

Effects of Supplementation With PUFAs and Antioxidants for Contact Lens Discomfort

NCT04163328 ↗

Phase 4 Terminated 31 enrolled University of Alabama at Birmingham
RandomizedParallel-groupQuadruple-blindTreatment

Summary

HydroEye® is a dietary omega 3 fatty acid supplement that contains both EPA and DHA, as well as GLA and ALA in the form of black currant seed oil. It also has vitamins A, E, C, B6, and magnesium, many of which are involved in fatty acid metabolism. In 2013, Sheppard et al. tested HydroEye® in dry eye patients who were not contact lens wearers and found that symptoms and corneal smoothness improved in response to HydroEye® supplementation. To date, HydroEye® has not been assessed in patients with contact lens discomfort; therefore, the purpose of this clinical trial is to determine the efficacy of HydroEye® as a treatment for contact lens discomfort.

Timeline

Start
2022-09-16
Primary completion
2024-08-21
Completion
2024-08-21

Outcome

Outcome not reported

Stopped (Enrollment): “COVID disruptions to recruitment and study completion, unforeseen staffing and other issues”

Drugs

EvaluationDrugModalityDoseRoute
Subject HydroEye® Unknown — Oral

Indications